Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

HYTN partners with 4C LABS

HYTN Innovations has established international manufacturing and pricing agreements with 4C LABS, an importer and distributor of cannabis-based pharmaceuticals in the United Kingdom.

These agreements aim to enable the production of cannabis products in bulk and final packaged forms for distribution in the UK and other global markets. Through this partnership HYTN will act as the manufacturer, packager and exporter of pharmaceutical quality cannabis goods that 4C LABS may purchase and subsequently import and distribute into the UK market.

HYTN's Good Manufacturing Practice (GMP) license, granted by Health Canada, and its PIC/S certification from Australia's Therapeutic Goods Administration (TGA), are key credentials that enable partnerships with internationally accredited distributors, these credentials, combined with 4C LABS' expertise and licenses in cannabis operations in the UK, create a robust foundation for the business collaboration with 4C Labs. Under the Agreements, HYTN intends to manufacture new products for 4C LABS while also serving as a co-manufacturing center for the production of existing products currently produced at various locations, to enhance operational efficiency for both companies. The agreements do not provide for a fixed, mandatory, or minimum order by 4C LABS.

"This partnership validates the ongoing regulatory work HYTN has been undertaking," stated Elliot McKerr, Chief Executive Officer of HYTN. Adding "By integrating 4C Labs' deep understanding of cannabis procurement and consumer demand with our advanced GMP-certified manufacturing processes, we are well-positioned to deliver high-quality cannabis products to international markets. This collaboration not only highlights our commitment to expanding the company's global presence but also marks a significant milestone in HYTN's advancement into non-sterile pharmaceutical production."

Greg Dobbin, Chief Executive Officer of 4C LABS, added, "Partnering with HYTN provides us with a significant competitive advantage. HYTN's proximity to high quality Canadian cannabis flower, coupled with their rigorous adherence to GMP standards and innovative manufacturing platform, will allow us to work towards delivering top quality products and competitive pricing to our customers."

Source: Globe News Wire.

Publication date: